Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
AZD1208
i
Other names:
AZD1208
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(4)
News
Trials
Company:
AstraZeneca
Drug class:
PIM inhibitor
Related drugs:
‹
MEN1703 (2)
EC-70124 (1)
AUM302 (0)
INCB53914 (0)
MEN1703 (2)
EC-70124 (1)
AUM302 (0)
INCB53914 (0)
›
Associations
(4)
News
Trials
VERI cancer hierarchy
Reset Filters
PIM1 mutation
Diffuse Large B Cell Lymphoma
PIM1 mutation
Diffuse Large B Cell Lymphoma
venetoclax + ibrutinib + AZD1208
Sensitive: D – Preclinical
venetoclax + ibrutinib + AZD1208
Sensitive
:
D
venetoclax + ibrutinib + AZD1208
Sensitive: D – Preclinical
venetoclax + ibrutinib + AZD1208
Sensitive
:
D
PAI1 expression
Rectal Cancer
PAI1 expression
Rectal Cancer
AZD1208
Sensitive: D – Preclinical
AZD1208
Sensitive
:
D
AZD1208
Sensitive: D – Preclinical
AZD1208
Sensitive
:
D
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
quizartinib + AZD1208
Sensitive: D – Preclinical
quizartinib + AZD1208
Sensitive
:
D
quizartinib + AZD1208
Sensitive: D – Preclinical
quizartinib + AZD1208
Sensitive
:
D
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
gilteritinib + AZD1208
Sensitive: D – Preclinical
gilteritinib + AZD1208
Sensitive
:
D
gilteritinib + AZD1208
Sensitive: D – Preclinical
gilteritinib + AZD1208
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login